


CENTER Ventures (4123.TWO)  
2025 Q3 Highlights




AUM USD1.2+B | NAV USD1.71  
29 Portfolio Companies | 13 IPOs

Release Date: November 14, 2025  
Source: Market Observation Post  
System (MOPS) / Official Press Release

AUM Growth




Earnings Driven by Investment Portfolio




Cash Inflow (USD)

- Divestment of FVTPL: 11.5M
- Divestment of Equity Method: 12.5M
- Dividend Income: 5.2M
- Total Cash Inflow: ~29.2M

Liabilities & Equities



NAV Profile (Market Value Basis)



Core Business Investments MOIC

Jacobio	Lumosa	Medeon	BioDlink	BioGend	Mycenax
21.69x	9.35x	3.66x	2.95x	1.58x	0.80x
Avg. 6.67x					

Portfolio Highlights



1167.HK  
Stake 10%  
Market Cap: ~\$0.7B

- Stock Performance: Share price surged >683% YTD, returning to 2023 highs
- Key Milestone: 2025.5 G12C inhibitor “Glecirasib” approved for China launch
- Valuation Potential: Comparable to Revolution Medicines (RVMD, >\$10B USD market cap), implying >10x upside



6535.TWO  
Stake 35%  
Market Cap: ~\$0.8B

- Expected to complete US FDA Type C Meeting by year-end
- Initiating Phase III clinical trials in China
- Entering global licensing phase for core pipeline



6499.TWO  
Stake 26%  
Market Cap: ~\$0.4B

- High-end minimally invasive medical device innovator and CDMO.
- Urocross , the world’s least invasive BPH solution, achieved clinical readout.
- Targeting FDA approval in 2026.
- Global out licensing is on processing.